Page last updated: 2024-12-08
donitriptan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
donitriptan: a 5-HT(1D) agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 197706 |
| CHEMBL ID | 1742428 |
| SCHEMBL ID | 1388876 |
| MeSH ID | M0333248 |
Synonyms (24)
| Synonym |
|---|
| gtpl39 |
| L000746 |
| donitriptan |
| 4-[4-[2-[[3-(2-aminoethyl)-1h-indol-5-yl]oxy]acetyl]piperazin-1-yl]benzonitrile |
| 1-(((3-(2-aminoethyl)indol-5-yl)oxy)acetyl)-4-(p-cyanophenyl)piperazine |
| 70968bvh2j , |
| 1-(((3-(2-aminoethyl)indol-5-yl)oxy)acetyl)-4-(p-cyanophenyl)piperazine. |
| donitriptan [inn] |
| unii-70968bvh2j |
| 170912-52-4 |
| CHEMBL1742428 |
| donitriptan [who-dd] |
| SCHEMBL1388876 |
| DTXSID20168974 |
| benzonitrile,4-[4-[2-[[3-(2-aminoethyl)-1h-indol-5-yl]oxy]acetyl]-1-piperazinyl]- |
| NCGC00370895-01 |
| EP5 , |
| 2-[5-[2-[4-(4-cyanophenyl)piperazin-1-yl]-2-oxidanylidene-ethoxy]-1~{h}-indol-3-yl]ethylazanium |
| HY-106157 |
| Q19597008 |
| NCGC00370895-03 |
| CS-0025002 |
| MS-26890 |
| AKOS040733006 |
Research Excerpts
Overview
Donitriptan is a potent, high efficacy agonist at 5-HT(1B/1D) receptors.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Donitriptan is a potent, high efficacy agonist at 5-HT(1B/1D) receptors. " | ( Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Avezaat, CJ; Bogers, AJ; John, GW; MaassenVanDenBrink, A; Mulder, PG; Saxena, PR; van den Broek, RW, 2002) | 2.03 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 15.0916 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 1.6933 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 18.9991 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 1.6933 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 1.6933 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 1.6933 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 1.6933 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (45)
Molecular Functions (18)
Ceullar Components (22)
Bioassays (21)
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.89) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||